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Background: Anxiety and mood disorders involve a high disease burden and are 
associated with high economic costs. A stepped-care approach intervention and 
abbreviated diagnostic method are assumed to increase effectiveness and efficiency of 
the mental healthcare and are expected to reduce economic costs. 
Methods: Presented are the rationale, design, and methods of a two-armed randomized 
controlled trial comparing ‘treatment as usual’ (TAU) with a brief intensified cognitive 
behavioral therapy (CBT) and/or pharmacotherapy. Eligible participants (N= 500) of five 
Dutch outpatient Mental Healthcare Centers are randomly assigned to either TAU or to 
the experimental condition (brief CBT and/or pharmacotherapy). Data on patients’ 
progress and clinical effectiveness of treatment are assessed at baseline, post-treatment 
(3 months after baseline), and at 6 and 12 months post-treatment by Routine Outcome 
Monitoring (ROM). Cost analysis is performed on the obtained data.  
Discussion: Since few studies have investigated both the clinical and cost effectiveness 
of a stepped-care approach intervention and a shortened diagnostic ROM method in 
both anxiety and/or mood disorders within secondary mental health care, the results of 
this study might contribute to the improvement of (cost)-effective treatment options and 
diagnostic methods for these disorders.  
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Anxiety and mood disorders belong to the most common mental disorders. 
Several epidemiological surveys found anxiety and mood disorders to be the 
most prevalent class of mental disorders in the general population [1,2]. The 
World Health Organization surveys estimated their global lifetime prevalence to 
be 14.3% and 10.6%, respectively [1,3]. These disorders frequently start early in 
life and tend to have a chronic or relapsing course [4]; moreover, their presence 
contributes to a high disease burden for both the patient and their family [3]. They 
also have a substantial impact on daily functioning at home/work and on quality 
of life [5-8], comparable to the impact and effects of major chronic illnesses 
[5,9,10]. Consequently, the economic costs of these disorders for healthcare 
systems and society are high [11]. It is estimated that in 2010 the direct and 
indirect costs of anxiety and mood disorders in Europe were 74.4 + 113.4 billion 
euro, respectively [12]. Earlier studies in the USA and UK reported even higher 
estimates [13].  
In the last decades, evidence-based treatments for anxiety and mood 
disorders have become available, i.e. cognitive behavioral therapy (CBT) and 
interpersonal therapy specifically developed for these disorders, as well as 
pharmacotherapy (mainly antidepressants) [14,15]. As important differences in 
effectiveness between the treatments are absent [13] guidelines were developed 
advocating a stepped-care model [16,17]. Moreover, to enhance effectiveness, 
for each of these treatments protocols and guidelines became available based on 
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those used in randomized controlled trials (RCT) [4,18-20]. Recently, we added 
Routine Outcome Monitoring (ROM) to the stepped-care approach to help the 
diagnostic process and treatment evaluation [19,20].  
It is clear that guidelines, protocols and ROM have the potential to improve 
treatment efficacy. However, these improvements may not yet be fully realized as 
adherence to the guidelines and protocols remains questionable [17,21-23], even 
when ROM is added [19,20]. This implies that treatments last longer, consist of 
too many sessions and, thus, unnecessarily prolong suffering and increase 
related costs [17,21,22]. Moreover, the current economic situation offers a strong 
incentive to make treatments as cost-effective as possible. This applies not only 
to the treatments as such, but also to ROM; from an economic point of view ROM 
should be as concise as possible. 
As most patients are treated in the first phase of the stepped-care model, 
it is in this phase that cost reduction is most profitable. Brief therapy is suggested 
to be suitable as a first step in a stepped-care model [22,24].  
This paper describes an RCT designed to evaluate the effects and costs 
of a shortened first treatment in the stepped-care protocol for anxiety and mood 
disorders in secondary care, an area where there is a paucity of research.  
It consists of time-limited (brief) CBT and/or medication treatment using a 
protocol following the multidisciplinary guidelines, but confined to a 7-week period 
and a maximum of 7 sessions. Also examined is the feasibility of a shorter, less 
labor-intensive ROM. In addition, the cost-effectiveness of the treatment and the 
adapted ROM are compared to ‘treatment as usual’ (TAU). 
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2. Design and Method  
 
2.1. Study goals  
Primary aim of this study is to evaluate the efficacy and effectiveness of a newly 
developed time-limited (brief) therapy intervention compared with TAU. 
Secondary aim is to evaluate the cost-effectiveness of the experimental 
intervention as compared with TAU.  
Additionally, the feasibility of a shortened, less work intensive and time-
consuming ROM is evaluated. Patient and therapist satisfaction with the new 
intervention is also explored.  
 
2.2. Study design 
The study is a pragmatic, two-armed RCT using a parallel group design. Five 
Dutch mental health clinics are projected to enroll a total of 500 participants over 
an 18-month period of active recruitment. Eligible participants who provide 
informed consent are randomly assigned to one of two groups: the control group 
(TAU), or the experimental group. Patients in both groups are assessed by ROM 
at baseline and after 3 months (post-treatment). Follow-up assessments are 
conducted in all patients at 6 and 12 months post-treatment. 
 Primary and secondary outcomes are assessed by ROM. Primary 
outcomes are the scores on the Web Screening Questionnaire (WSQ) and Brief 
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Symptom Inventory (BSI). Secondary outcomes are the scores on the other 
instruments assessed by ROM (see section 2.8.1 and Table 1).  
The design and methodology of this study allows to assess analysis of 
equivalency (non-inferiority), since we do not expect to find the introduced 
intervention to be superior to TAU.  
 
2.2.1. Control Group (TAU) 
Individuals assigned to the control group receive standard psychiatric treatment 
called; Treatment As Usual (TAU). TAU varies across centers depending on the 
current activities at the participating MHCs. In MHCs, TAU is not strictly 
formalized; a multidisciplinary team is free to assign a therapy from a wide range 
of evidence-based therapeutic options (including: pharmacotherapy and 
psychological treatment, psychosocial interventions, contact with a psychiatric 
test nurse) according to the stepped-care approach. The treatment decision is 
based on professional experience, taking into account the specific problems and 
characteristics of the individual patient. The number of sessions depends on the 
therapy that is offered and can be weekly or (almost always) at a lower frequency 
of sessions, and are not confined to a maximum of sessions.  
 
2.2.2. Experimental Group 
The experimental group receives a brief, intensified cognitive CBT and/or 
pharmacotherapy confined to a fixed time period (7 weeks) and a limited number 
of weekly sessions (maximum 7 sessions within 7 weeks). The offered CBT and 
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pharmacotherapy are described in more detail in section 2.9. An intake and 
outtake session are also involved when in the experimental group (described in 
section 2.8.2).  
 
2.3. Study setting 
The study is conducted at five outpatient mental health clinics from the Dutch 
Regional Mental Health Provider (RMHP) Rivierduinen (RD). 
RD provides secondary mental health care for an area with over one million 
inhabitants. In the Netherlands access to mental health care is easy and is not 
limited by insurance or the financial means of the individual patient. Health 
insurance is compulsory for all citizens and regulated by the government [25,26]. 
The Dutch mental healthcare system is organized in a stepped-care manner and 
uses evidence-based treatment guidelines. According to a stepped- care 
approach a brief but intensive first step is offered and patients who are 
insufficiently helped by the initial intervention are allowed to ‘step up’ to 
subsequent treatment [16]. The therapeutic principles within the treatment 
protocols of the intervention are referred to as a ‘first step’ of a stepped-care 
approach. 
 
2.4. Participants  
Eligible participants are males and females aged 18 to 65 years, currently 
diagnosed with an anxiety and/or depressive disorder as main diagnosis. 
Patients with current psychotic or bipolar traits, homicidal or suicidal risk or 
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severe social dysfunction, as diagnosed by their general practitioner (GP), 
psychiatrist, or as assessed in a diagnostic interview, are excluded. All eligible 
subjects need to have adequate understanding of the Dutch language.  
Patients with the following DSM IV [27] diagnoses are therefore included: 
minor or major depressive disorder (single episode or recurrent), depressive 
disorder NAO, dysthemia, panic disorder (with or without agoraphobia), panic 
disorder NAO, social phobia, simple phobia, generalized anxiety disorder, 
obsessive compulsive disorder, posttraumatic stress disorder (type I or single 
trauma), adjustment disorder (with anxiety and/or depressive mood).Co-morbidity 
associated with other psychiatric diagnoses (with the exception of psychotic or 
bipolar disorder) is allowed in order to establish a clinically relevant, broadly 
representative sample.  
 
2.5. Sample size 
The sample size was calculated using the method of Cohen [28] and based on 
review of the available literature of earlier comparable studies. We aimed at 
detecting an equivalence with an acceptable difference of 5% on the primary 
outcome measures WSQ and BSI (see section 2.8.1 and Table 1) and a 15% 
maximal difference in outcome scores between TAU and the intervention under 
the usual assumptions of an α = 0.05 and power of 80%. This results in an 
intended total sample size of 500 participants. 
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2.6. Recruitment, screening and enrolment procedures  
All patients referred by their GP to one of the participating MHCs for the 
treatment of anxiety and/or mood disorders are, initially, eligible to participate in 
the study.  
We adopted the following steps in recruitment: first, all referred patients 
are globally screened by an experienced psychiatrist for the presence of 
depression and/or anxiety disorders as current, main problem. This global 
screening is based on written information provided by the GP containing an 
interpretation of the patient’s current health status and referral for further mental 
health care; this step does not require face-to-face contact with the patient. 
Subsequently, the potentially eligible patients are invited for a first ROM 
assessment. Prior to this first ROM assessment, the psychiatric research nurse 
conducting the ROM assessment invites the patients to participate in the study. 
Those who agree to participate are asked to provide written informed consent.  
When informed consent is given, the baseline ROM assessment (T1) 
according to the study design is conducted. After completion of this assessment, 
participants’ randomization by the research team takes place (see section 2.7). 
Depending on the randomized treatment condition, final eligibility is assessed 
during the subsequent intake session by means of the inclusion and exclusion 
criteria of the study.  
Patient enrollment began March 1, 2010 and will end December 31, 2011. 
Follow-up assessment is ongoing and is projected to continue until December 31, 
2012.  
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2.7. Randomization and blinding  
After successful screening, provision of written informed consent and completion 
of the baseline measurement (T1); (see section 2.6), all eligible participants in 
this RCT are randomly assigned to one of two groups: the experimental group or 
the control group (TAU). Random allocation was generated by using a variable 
blocked design developed by an independent researcher from the Department of 
Medical Statistics & BioInformatics, LUMC and derived by computer. 
Randomization takes place on the individual level by clinical center (n = 5) and 
gender. This procedure is used to increase the likelihood that the distribution 
between groups is balanced on the two potentially important confounding 
variables and to conceal random allocation sequence.  
Participants and clinicians are informed about the outcome of the randomization; 
the psychiatric test nurses (assessors) involved in the ROM assessment in the 
study, are kept blinded to the randomization condition throughout the entire 
study.   
Randomization and the subsequent assignment of participants to the intervention 
will be performed by the researcher (D.M.), whom is not an assessor.  
 
2.8. Assessment 
For both treatment conditions assessment information is obtained in two-fold, as 
shown in Figure 1.  
 
 Insert Figure 1 here. 
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First, patients participating in this study are assessed by ROM (see 2.8.1.) 
at four time intervals: 1) T1 at baseline (start of study), 2) T2 immediately post 
treatment (3 months after baseline measurement), 3) T3 6 months post-treatment 
(first follow-up measurement), and 4) T4 12 months post-treatment (second 
follow-up measurement). The second assessment method is provided by an 
intake and outtake evaluation (see also 2.8.2).  
The timetable of assessments is shown in Figure 1.  
 
2.8.1. Routine Outcome Measures and feedback 
This study is conducted on data collected using ROM [19]. ROM is a monitoring 
system for patient care, implemented in 2002 in the outpatient clinics of RD and 
the Department of Psychiatry of the LUMC. All outpatients referred to these 
clinics by their GP for treatment of a mood, anxiety and/or somatoform disorder, 
are assessed by ROM.   
ROM periodically measures the presence and severity of psychiatric 
symptoms in patients and thereby monitors patients’ progress/changes during 
treatment by conducting an extensive battery of psychometric instruments. An 
overview of the instruments used in ROM is available at 
http://www.lumc.nl/psychiatry/ROM-instruments.  
These instruments are routinely assessed at baseline and during 
treatment at several time points [19,29]. The baseline assessment also 
comprises a standardized diagnostic interview (Dutch version of the Mini-
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International Neuropsychiatric Interview Plus, version 5.0.0) [30,31], the 
collection of socio-demographic and socio-economic data, and the administration 
of general measures of health and disease-specific severity scales.  
Instruments are both self-report and interviewer based. All interviewer- 
based instruments are carried out by a psychiatric research nurse and the self-
report questionnaires are completed using a touch-screen computer. A web-
based software QuestManager (www.psyquestmanager.nl) was developed to 
assist the ROM method and is also used in the current study.  
Data collected by ROM are provided to the clinician and patient as written 
feedback (a brief report) by the psychiatric research nurse. This written feedback 
consists of an overview of the main measurement results. Furthermore, a 
summary of the diagnostic interview and a summary of the main questionnaires 
is given (one or two pages). The clinician shares and discusses these results with 
the patient. The assessment outcomes are used to support decision-making for 
the future course of the treatment [19,29].  
For the present study, all eligible patients are routinely assessed by ROM. 
Table 1 lists the instruments used to assess the disorders of interest for the 
current study. To further test the hypotheses of the present study, five additional 
questionnaires are added to the regular ROM and are indicated (in bold print) in 
Table 1.  
 
 Insert Table 1 here.  
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Similar to the regular ROM, the baseline assessment comprises the 
standardized diagnostic interview, MINI-Plus 5.0.0, and the collection of socio-
demographic and socio-economic data.  
For the present study, the written ROM feedback depends on the 
randomized treatment condition. Clinicians in the experimental group are 
provided with minimal information about the results of the questionnaires, i.e. an 
overview of the results of the patient’s performance on the two primary outcome 
measures: the Web Screening Questionnaire (WSQ) [32] and the Brief Symptom 
Inventory (BSI) [33]. The summary of the diagnostic interview and information 
about the other measures is left out. Clinicians in the TAU group are provided 
with the regular, extensive, feedback about all measurement results.  
 
2.8.2. Intake and outtake 
In addition, to examine the progress of patients’ wellbeing and the effectiveness 
of the treatment, an intake and outtake session is included in the study design 
(Figure 1). Both intake and outtake session are semi- structured and conducted 
by the same experienced psychiatrist (see 2.8.5), during one 45 minute 
(approximately) session.  
The intake takes place before the start of the treatment, after the ROM 
baseline measurement. A semi-structured clinical interview, especially designed 
for this study, is administered. Compared to a regular intake, this intake session 
is protocolized, shorter and more structured. Moreover, the intake aims to ensure 
that the patient is eligible to participate in this study by means of the in- and 
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exclusion criteria (section 2.4). Personal data, including demographics and the 
current clinical picture, are also obtained during this intake session. 
The outtake evaluation takes place within (maximally) 2 weeks post-
treatment (Figure 1) and is part of a stepped-care approach. The aim of this 
semi- structured outtake session is to evaluate if patients are sufficiently helped 
by the offered initial intervention or ‘stepping up’ to subsequent (additional) 
treatment is necessary. The ‘stepping-up’ is according to clinical experience and 
the local and national guidelines as handled by the involved MHC. During the 
outtake the progress of the patient’s symptoms and his/her current clinical status 
will be assessed. Furthermore, it evaluates the patient’s wellbeing and an ‘end 
diagnosis’ is formulated. A possible subsequent treatment plan can be discussed 
by patient and clinician.  
When the outtake session demonstrates that the achieved treatment effect 
is insufficient, the patient is offered to ‘step up’ to additional treatment according 
to the treatment guidelines in the same MHC, or elsewhere.   
 
2.9. Treatment   
For the current study the following treatment protocols are formulated by the 
research team:  
1. Pharmacotherapy protocol for mood and/or anxiety disorders (maximum 4 
sessions within 7 weeks) 
2. Brief Cognitive Behavioral Therapy protocol for depression (minimal 5, 
maximum 7 weekly sessions) 
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3. Brief Cognitive Behavioral Therapy protocol for anxiety (minimal 5, 
maximum 7 weekly sessions) 
4. Eye Movement Desensitization and Reprocessing (EMDR) therapy 
protocol for post-traumatic stress disorder (PTSD) (maximum 6 sessions 
within 7 weeks) 
 
The treatment decision was made by the patient and therapist, based on the 
professional experience of the therapist and taking into account the specific 
disorder and characteristics of the individual patient, thereby acknowledging the 
patient’s preferences as is good practice and according to the common accepted 
principles of shared-decision making [34,35].   
The treatment protocols are based on the existing treatment guidelines 
described in the (multidisciplinary) guidelines in Dutch mental healthcare 
[4,36,37] and on acknowledged evidence-based literature [4,38-41]. All treatment 
protocols are evaluated during an outtake session (see section 2.8.2.). 
Delivering treatment by combining the described protocols is also possible. 
 
2.9.1. Pharmacotherapy for mood and/or anxiety disorders  
In the current study the pharmacotherapy protocol for mood disorders and/or 
anxiety is characterized by a quick onset and aims to reach an optimal clinical 
effect of the used medication, involving rapid stepping up to the most optimal 
dose and minimizing the side-effects for patients as much as possible. Patients 
are treated with a selective serotonin reuptake inhibitor (SSRI) in 4 sessions 
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within a 7-week period. Medication use is evaluated after this fixed period and 
continued when necessary. The protocol provides a scenario for patients when 
not using an SSRI (SSRI 1 condition) or, on the other hand, a scenario for 
patients with a history of (sufficient and adequate) SSRI use and now starting 
with a new different SSRI (SSRI 2 condition). When patients are currently using 
an SSRI (as prescribed by their GP), medication is continued and when 
necessary adapted according to the pharmacotherapy protocol.  
 
2.9.2. Brief CBT for depression 
The brief CBT for depression protocol is focusing on decreasing the depressive 
mood of the client and maintain this improvement and based on the cognitive 
behavioral therapy manuals/protocols for depression [38,42].  
For the current study this protocol is confined to a maximum of 7 weekly sessions 
(minimal 5 sessions) within a 7 week time-period. The first 3 sessions of this brief 
CBT protocol are dedicated to activation-enhancement and training of social 
skills. The last 4 sessions emphasizes tracing and altering irrational cognitions by 
challenging them [38,42]. Each treatment session consists of a 45-min face-to-
face contact and is characterized by a quick onset (no waiting list).  
 
2.9.3. Brief CBT for anxiety  
The brief CBT protocol for anxiety disorder is also characterized by a quick onset 
(no waiting list) and a maximum number of sessions (minimal 5, maximum 7 
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weekly sessions within a 7-week period). Each treatment session consists of a 
45-min face-to-face contact.  
The main focus of the brief CBT for anxiety protocol is on the core CBT 
techniques for the treatment of anxiety disorders: anxiety/tension- reducing 
techniques, cognitive techniques and exposure techniques (used when 
adequate) [40]. If dysfunctional worrying is interfering, anti-worrying techniques 
are offered.  
 
2.9.4. Eye Movement Desensitization and Reprocessing Therapy  
The EMDR therapy for the PTSD protocol is characterized by a quick onset (no 
waiting list) and a limited number of sessions (a maximum of 6 sessions within 7 
weeks). Furthermore, all EMDR sessions comprise a 45-min face-to-face contact. 
The EMDR protocol of this study is based on the Dutch Manual EMDR [43] and 
approved principles described in the literature [39], or the treatment of PTSD for 
patients suffering from a Type I trauma or single trauma.  
 
2.10. Therapist selection, training and supervision 
The treatment protocols are performed by experienced clinicians: psychiatrists 
and psychologists working at the participating MHCs.  
Clinicians working at RD provide treatment in accordance with the 
multidisciplinary guidelines of the National Steering Committee describing 
evidenced-based treatments for mood and anxiety disorders. The participating 
clinicians are all professionally educated and trained in CBT. Years of experience 
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ranged between 1- 7 years. They were especially trained to work with the brief 
treatment protocols within this study.  
The participating clinicians were initially instructed by the research team. 
Two hours of instructions were provided for participating clinicians on two 
consecutive days. On the first day, a 2-hour instruction was provided for 
clinicians involved in the CBT condition. During this instruction, the EMDR 
protocol was also introduced. On the subsequent day, a 2-hour instruction was 
provided for clinicians involved in providing the pharmacotherapy within this 
study.  
During these instruction meetings, consensus was achieved on a number 
of core elements of the treatments. Furthermore, the content of future supervision 
session for all involved clinicians was discussed.  
Clinicians in the TAU group received no specific training from the research 
team. They provide the usual treatment to the patients; globally following the 
available multidisciplinary treatment guidelines, since adherence is questionable.  
Furthermore, six certified psychiatric test nurses were trained by the 
research team to assess the ROM measurements according to the guidelines of 
the study. The research nurses are all trained and certified to assess ROM 
measurements.  
Instruction was given on the administration and reporting of the ROM 
measurements designed for this study. The psychiatric test nurses were informed 
about the logistics of the study and how to apply the blinding method used in the 
present study.  
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Once every 3 months supervision sessions were organized by the 
research team for the clinicians and the psychiatric test nurses. Interview 
techniques, how to avoid protocol violations and other challenges were discussed 
and evaluated. 
 In addition, unrestricted support is provided to all study clinicians and 
psychiatric test nurses via email and through visits made by the research team.  
 
2.11. Fidelity monitoring 
All treatment sessions within the brief CBT protocols will be audio-taped, 
using a digital voice recorder to ensure treatment protocol fidelity. The taped 
treatment sessions will be randomly checked and scored on protocol consistency 
and reliability by the research team. Furthermore, therapist adherence and 
satisfaction will be monitored using an evaluation questionnaire. This evaluation 
questionnaire furthermore monitors the delivery and compliance of the different 
treatment protocols since it questions how many sessions were involved and if 
treatment was successfully delivered. This evaluation questionnaire, and the list 
of the criteria for protocol consistency and reliability, can be obtained from the 
corresponding author. 
 
2.12. Statistical analyses   
Descriptive statistics will be used to describe the characteristics of the two 
groups, and the outcome variables, at the four measurement points. To evaluate 
potential group differences at baseline, post-treatment and at the 6 and 12-month 
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follow-up measurements, repeated measures analysis will be conducted to 
analyze the short and long-term effects between the experimental and control 
group.  
All analyses will be conducted according to the intention-to-treat (ITT) 
approach. Additionally, analysis per protocol will be conducted. 
Chi-square analyses and t-tests for independent samples will be used for 
data measured on one occasion (e.g. patient satisfaction, therapist satisfaction, 
baseline demographic features) to detect possible differences between the two 
groups. Differences are considered statistically significant at p < 0.05.   
Missing values will be imputed with regression imputation techniques. 
Generalized Estimating Equation (GEE) analyses will additionally be performed 
on the dataset with missing data and when missing values are imputed. Analyses 
adjusting for cluster effects will be performed when analyzing the data. 
 All analysis will be done using SPSS (version 17, Windows).  
 
2.12.1 Health economics analysis 
Cost-effectiveness will be also calculated. An economic evaluation based on the 
TIC-P questionnaire (see Table 1) examines the costs and other aspects of the 
study protocol. Direct costs per patient in the experimental condition versus the 
costs per patient in the control condition will be compared. Costs are validated by 
reference; if these references are not available, costs will be estimated by costs 
research.  
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Cost or product losses are verified by the ‘friction cost method’ [44].The 
friction cost method estimates the indirect costs of disease, which explicitly 
considers economic circumstances that limit production loss due to disease. 
According to this method, these indirect costs mainly occur during the time it 
takes to replace a worker, i.e. the friction period [45].  
 
2.13. Approvals and data/safety monitoring 
The study protocol was approved by the Medical Ethical Committee (MEC) 
of the Leiden University Medical Center (LUMC). After full verbal and written 
information about the study, written informed consent was obtained from all 
participants at the start of baseline assessment. To safeguard the anonymity of 
the patients and to ensure proper handling of the data, processing of all data is in 
accordance with a comprehensive protocol: the Psychiatric University Network 
REgistration Leiden (PAREL-regulations). The MEC of the LUMC approved the 
regulations of this protocol and agreed with this policy [19]. Confidentiality of data 
is maintained by using a unique research identification (ID) number for each 
participant, which enables to identify individuals without using names. Only a 
limited number of persons (researcher) have access to the record that links the 
ID number to identifiable information.  
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3. Current status and demographics of sample 
Data will be collected until at least December 31, 2012. At the time of completion 
of this paper, the inclusion period of the study is still ongoing. A total of 161 
patients have completed the baseline measurement. Their preliminary socio-
demographic and clinical characteristics are presented in Table 2.  
 
> Insert Table 2 here.  
 
These 161 participants are evenly distributed across both groups; 79 in the TAU 
group and 82 in the experimental group. Demographic data (educational and 
employment status, and ethnic background) are missing for 4 patients. Moreover, 
for 12 patients the MINI-Plus diagnostic interview did not lead to a DMS-IV 
classification in ROM; therefore, only a clinical diagnosis is available for these 
patients.    
At baseline there were no significant differences in demographic data 
between the two groups. The mean age of the patients is 37.2 (SD 11.5; range 
18-65) years, and there is a similar distribution for gender (61.5% female and 
38.5% male) in both groups.  
Furthermore, the participants comprise a relatively homogeneous group 
with common mental disorders, i.e. mainly mood and anxiety disorders. The 
majority of the included patients have more than one clinical diagnosis.  
At baseline, of all patients 45.3% had an anxiety disorder only, and 37.9% 
were diagnosed with depression only. In total, 15.5% of the patients were 
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diagnosed with both an anxiety and mood disorder. This distribution was similar 
in both treatment arms (Table 2).  
 
4. Discussion 
Evidence-based clinical guidelines advocating a stepped-care approach 
are available in mental healthcare and have demonstrated success in the 
treatment of mood and anxiety disorders [46]. Progress within these stepped-
care approaches is carefully monitored and patients are able to ‘step up’ when no 
subsequent improvement occurs [16].  
However, initiation of and adherence to these recommended and effective 
treatments within these guidelines is usually poor [18].The optimal content and 
organization of how to provide this stepped care is unclear, and implementation 
and acceptability of stepped care as a method of delivering psychological/ 
psychiatric services has not yet been adopted [21,22]. Little information is 
available about how stepped care should be effectively implemented [22] and 
only a few randomized trials present convincing evidence and evaluations of both 
the cost and clinical effectiveness of this stepped-care model. Most studies 
investigated either the cost effectiveness [47,48] or the clinical effectiveness [49-
52] of stepped care. When simultaneously investigated, the studies examined the 
effectiveness of a stepped-care model for patients with either a mood disorder 
[53] or an anxiety disorder [54], and only in primary care.   
The present study aims to examine the clinical effectiveness and cost 
effectiveness of an innovative stepped-care intervention for patients (aged 18-65 
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years) with anxiety and/or mood disorders in secondary care. To carefully 
monitor the patient’s progress, the ROM method is added.  
To our knowledge this is the first long-term study to simultaneously 
analyze the clinical and cost effectiveness of a stepped-care approach in the 
treatment of both mood and anxiety disorders in a secondary care setting. The 
ROM method, monitoring patients’ progress at fixed time intervals with a follow-
up period of 1 year, allows to establish the long-term efficiency expectations of 
treatment success and effects on health status and economic costs. Moreover, 
for the current study, ROM is shortened and evaluated in terms of feasibility. 
Since the baseline characteristics of the participants in both the experimental and 
the control group show no significant differences, the study outcomes are 
expected to be highly generalizable.  
The findings of the present study will have potential implications for 
provision of the most convenient form of mental healthcare in the Netherlands. 
The offered time-limited, brief intervention could provide valuable information to 
help the development of an optimal treatment protocol for patients with anxiety 
and/or mood disorders. The limited number of sessions reduces the average 
amount of therapist input per patient and, moreover, is an adequate response to 
patient preferences for brief psychological interventions [55]. Since the 
intervention has not only fewer sessions but also an earlier start after intake, it is 
expected to reduce waiting lists; this is a common problem in the provision of 
mental healthcare.  
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Results of the analyses will allow to compare both the clinical (patient 
improvement) and cost effectiveness (economic costs of the intervention) 
between the experimental intervention and TAU. Besides answering our primary 
question (‘is the experimental intervention at least as effective as providing 
regular care, i.e. treatment as usual’) these analyses are expected to provide 
insight into how to increase the quality and efficiency of care. The experimental 
intervention is expected to reduce costs and increase efficiency on (at least) the 
short term. The study design will also provide insight into long-term effects, 
possibly encouraging the implementation of an effective stepped-care model in 
mental healthcare.  
Apart from evaluation of the effectiveness of the intervention, the study 
also examines what works best for the individual patient. The broad inclusion 
criteria allow the recruitment of patients with a wide range of mood and/or anxiety 
disorders. The resulting sample is then broadly representative of the patient 
population commonly referred to outpatient mental healthcare centers in the 
Netherlands. No indication of a selection bias is expected and, since the ROM 
method outlines patient characteristics, the advantages of the experimental 
intervention for the individual patient can be clearly assessed.  
A major strength of this study is that it is a pragmatic randomized trial. In 
such trials, patients and therapist are the same as those encountered in daily 
practice. Care is provided by healthcare professionals from the field and, since 
the sample of patients is the same as those seen in daily practice, this enhances 
the external validity of the study. Moreover, since the stepped-care algorithm 
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used covers the whole continuum from enrollment, diagnostics, assessments and 
treatment, this study reflects the ‘real’ effects of daily practice thereby allowing 
generalization and implementation of any beneficial logistical and organizational 
effects in (clinical) practice.  
However, this advantage also carries some risks. Besides the logistic 
difficulties of implementing a pragmatic randomized trial, it is difficult to maintain 
treatment integrity when conducting a study in daily practice. We aim to minimize 
this limitation by means of our instruction meetings and supervision sessions for 
all clinicians and psychiatric test nurses involved. Moreover, since all treatment 
sessions within the brief CBT protocols are audio-taped, treatment protocol 
fidelity is closely examined and, hopefully, achieved.  
Moreover, since conducting a study in daily practice involves the 
possibility of combining CBT and medication therapy and enhances the 
possibilities of non-specific effects in therapy, the potential therapeutic benefit of 
the intervention can only be formulated with caution. 
While the design of the current study addresses many of the limitations of 
previous research, a preliminary reflection on further limitations and strengths of 
our design is required. Although homogeneous patient groups are expected in 
both treatment arms, the control group may have some nonspecific effects on the 
expected outcomes. For example, no control is made regarding the number of 
visits made by persons in the TAU group to their physicians. Therefore, it is 
possible that patients in the control group make fewer visits to their physician or, 
in some cases, no visits at all if they are still on a waiting list. Although this does 
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reflect daily practice, we cannot rule out the nonspecific effects of an increased 
number of visits and/or attention from physicians as an explanation for the 
(possible) better outcomes in the experimental group.  
Another limitation concerns the expected dropout rates at the four ROM 
measurement assessments, which may affect the results of the study. Although 
compliance with the ROM procedure is relatively successful, a 20% dropout rate 
is expected at reassessments. In response to these high attrition rates, the 
aggregated data are also analyzed according to the intention-to-treat analysis. 
This might yield a more valid reflection of the results and conclusions about the 
effectiveness of the experimental intervention.  
We have described the rationale and design of an RCT examining the 
clinical and cost effectiveness of a time-limited, stepped-care based intervention 
in the treatment of mood and anxiety disorders. This study is collecting a 
substantial amount of data which will improve our understanding of how to 
develop effective strategies to adequately diagnose and treat patients with mood 
and/or anxiety disorders in secondary care.  
If the experimental intervention proves to be as effective as regular care, 
this type of intervention could facilitate the growing need of providing the most 
optimal and (cost)-efficient mental healthcare. This study will hopefully elucidate 
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Fig. 1. Timetable of assessments during the study. 
  
Note: T1 : baseline assessment; T2: post-treatment assessment; T3: first follow-up assessment; T4: second follow-up 
assessment.  
Table 1. ROM study measures by time interval 
Instrument Full Name Domain Cluster Typea Time- interval
b Reference  
     T1 T2 T3 T4  
AGO Agoraphobic Cognitions Questionnaire Psychopath Spec SR X X X X [56] 
BDI-II Beck Depression Inventory version II Psychopath Spec SR X X X X [57] 
BSI Brief Symptom Inventory Psychopath Gen SR X X X X [33] 
CGI Clinical Global Impression Psychopath Gen OS X X X X [58] 
CTQ28 Childhood Trauma Questionnaire - 28  Psychopath Gen SR X    [59] 
DAPPsf Dimensional Assessment of Personality Pathology-  Short Form  Psychopath Gen SR X    [60] 
DAS -13 Dysfunctional Attitude Scale - 13 Psychopath Spec SR X X X X [61] 
DEMOG Demographic Inventory Soc Dem Gen SR X     
EVALr Evaluation Rating Psychopath Gen OS X X X X  
GAF Global Assessment of Functioning Psychopath Gen OS X X X X [62] 
H_Qc Health Questionnaire Soc Dem  Gen SR X     
Mental Healthcare Thermometerd  Dutch Mental Healthcare Thermometer  of Appreciation by Clients Cons Satisf Gen SR  X   [63] 
IES-R   Impact of Events Scale - Revised Psychopath Spec SR X X X X [64,65] 
III (Triple I) Interpretation of Intrusions Inventory Psychopath Spec SR X X X X [66] 
LSAS Liebowitz Social Anxiety Scale Psychopath Spec OS X X X X [67] 
MASQ Mood and Anxiety Symptom[32] Questionnaire  Psychopath Gen SR X X X X [68] 
MINI-Plus 5.0.0.  Mini- International Neuropsychiatric Interview Plus 5.0.0.  Psychopath Gen OS X    [30] 
MRS Mania Rating Scale Psychopath Spec SR X X X X [69] 
PADUA/PI-r Padua Inventory revised Psychopath Spec SR X X X X [70] 
PAI  Panic Appraisal Inventory Psychopath Spec SR X X X X [71] 
PDSS Panic Disorder Severity Scale Psychopath Spec OS X X X X [72] 
PSWQ Penn State Worry Questionnaire Psychopath Spec SR X X X X [73] 
SF- 36 Short Form Health Survey 36 Psychosoc Func Gen SR X X X X [74] 
SIAS Social Interaction and Anxiety Scale Psychopath Spec SR X X X X [75] 
SPS  Social Phobia Scale Psychopath Spec SR X X X X [75] 
TIC-P Trimbos/iMTA questionnaire for Costs  Cons Satisf  Gen SR X X X X [76] 
 38 
 
aSR=Self Report; OS=Observer Scale; bT1 : baseline assessment; T2: post treatment assessment; T3: first follow-up assessment; T4: second follow- up assessment; cHealth 
Questionnaire H_Q (in Dutch: Gezondheidsvragenlijst); dMental Healthcare Thermometer (in Dutch: GGZ Thermometer) 
 
Note: A list of all ROM measures is available at http://www.lumc.nl/psychiatry/ROM-instruments 
associated with Psychiatric Illness Cost-effect 
vCPRS Abbreviated Comprehensive Psychopathological Rating Scale Psychopath Gen OS X X X X [77] 
WDQ Worry Domains Questionnaire Psychopath Spec SR X X X X [78] 
WSQ Web Screening Questionnaire  for common mental disorders  Psychopath Gen SR X  X X [32] 
Table 2.  Socio-demographic and clinical characteristics of the eligible patients at 
baseline.  
 
   Randomized condition     





                  












 N                             %  N                                  %     
Age in years: mean (SD) 37.2 (11.5)  36.0 (12.8)  36.6 (12.1)   
          
Gender           .609 
Male  32                     40.5  30                            36.6  62   
Female 47                        59.5  52                             63.4  99   
          
Ethnic background c          .967 
Dutch 74                    93.7  72                             93.6  146   
Other ethnicity   5                           6.3    5                                6.4  10   
          
Educational statuscd           .968 
Lower education 30                        38.0  29                           37.7  59   
Higher education 49                   62.0  48                             62.3  97   
          
Employment statusc          .546 
Employed 45                   52.0  36                        46.8  81   
Unemployed/retired 13                        16.5  16                             20.8  29   
Work-related disability 17                        21.5  18                             23.4  35   
Other   4                         5.1    7                               9.1  11   
          
Marital statusc         .226 
Married/Cohabitating  38 48.1  45 58.4  83   
Divorced/separated/widow 11 13.9    5 6.5  16   
Single 30 38.0  27 35.1  57   
          
DSM IVe diagnosis (n, %)           
Any Depression 32                      19.9  29                         18.0  61   .501 
Any Anxiety disorder 31                    19.3  42                           26.1  73  .127 
Mood and Anxiety disorder 11                 6.8  14 8.7  25  .581  
Adjustment disorder (with 
anxious and/ore depressive 
symptoms)  
  2                1.2    2                           1.2  4  .970  
Post Traumatic Stress Disorder   8                        5.0    7                                4.3  15  .729  
Other 26 16.1  21 13.0  47  .308 
        
 
aTAU=Treatment As Usual; bCBT=Cognitive Behavioral Therapy; cDemographic data; ethnic background, educational 
status and employment status are missing for 4 participants; dLower education= basic education, primary education, no 
education at all. Higher education= Higher education, university; eDSM IV=Diagnostic Statistical Manual (of mental 
disorders) 4th version. 
 
Note: patients may have more than one diagnosis  
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